B. Metzler seel. Sohn & Co. AG Has $152.40 Million Position in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• B. Metzler seel. Sohn & Co. AG increased its stake in Vertex Pharmaceuticals by 289.2%, owning 314,343 shares valued at approximately $152.4 million at the end of the latest quarter.
• Vertex Pharmaceuticals reported a quarterly EPS of $4.52, exceeding analysts' expectations, with a revenue of $2.94 billion, a rise of 11.3% compared to the same quarter last year.
• The stock has a market cap of $99.27 billion, a P/E ratio of 27.68, and is currently down 0.5%, trading at around $387.18.

B. Metzler seel. Sohn & Co. AG increased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 289.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 314,343 shares of the pharmaceutical company's stock after buying an additional 233,584 shares during the quarter. Vertex Pharmaceuticals accounts for approximately 1.6% of B. Metzler seel. Sohn & Co. AG's investment portfolio, making the stock its 18th largest position. B. Metzler seel. Sohn & Co. AG owned approximately 0.12% of Vertex Pharmaceuticals worth $152,400,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Vertex Pharmaceuticals by 1.0% in the first quarter. Vanguard Group Inc. now owns 23,491,161 shares of the pharmaceutical company's stock valued at $11,388,985,000 after buying an additional 232,873 shares during the period. Jennison Associates LLC increased its position in Vertex Pharmaceuticals by 17.2% during the 1st quarter. Jennison Associates LLC now owns 5,062,442 shares of the pharmaceutical company's stock valued at $2,454,373,000 after purchasing an additional 744,680 shares during the period. Price T Rowe Associates Inc. MD increased its position in Vertex Pharmaceuticals by 72.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,917,227 shares of the pharmaceutical company's stock valued at $1,414,331,000 after purchasing an additional 1,226,527 shares during the period. Janus Henderson Group PLC increased its position in Vertex Pharmaceuticals by 12.6% during the 4th quarter. Janus Henderson Group PLC now owns 2,833,889 shares of the pharmaceutical company's stock valued at $1,141,277,000 after purchasing an additional 317,058 shares during the period. Finally, Northern Trust Corp increased its position in Vertex Pharmaceuticals by 15.0% during the 4th quarter. Northern Trust Corp now owns 2,721,049 shares of the pharmaceutical company's stock valued at $1,095,766,000 after purchasing an additional 355,057 shares during the period. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Stock Down 0.5%

Shares of VRTX opened at $387.18 on Wednesday. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.88. The business's fifty day moving average is $436.66 and its 200 day moving average is $460.13. The stock has a market cap of $99.27 billion, a P/E ratio of 27.68 and a beta of 0.44.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company had revenue of $2.94 billion for the quarter, compared to analysts' expectations of $2.90 billion. During the same period last year, the business earned ($12.83) EPS. Vertex Pharmaceuticals's quarterly revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Activity

In other news, Director Bruce I. Sachs bought 5,000 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The shares were bought at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the acquisition, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have weighed in on VRTX. Leerink Partnrs downgraded shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 6th. Morgan Stanley set a $439.00 target price on shares of Vertex Pharmaceuticals and gave the company an "equal weight" rating in a research report on Tuesday, August 5th. Wells Fargo & Company raised shares of Vertex Pharmaceuticals from an "equal weight" rating to an "overweight" rating and set a $460.00 price objective for the company in a research report on Wednesday, August 6th. UBS Group set a $553.00 price objective on shares of Vertex Pharmaceuticals and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Finally, Cantor Fitzgerald reduced their price objective on shares of Vertex Pharmaceuticals from $535.00 to $485.00 and set an "overweight" rating for the company in a research report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and thirteen have issued a Hold rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $497.10.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.